Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Preservation of cell-based immunotherapies for clinical trials.

Li R, Johnson R, Yu G, McKenna DH, Hubel A.

Cytotherapy. 2019 Sep;21(9):943-957. doi: 10.1016/j.jcyt.2019.07.004. Epub 2019 Aug 12. Review.

PMID:
31416704
2.

First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia.

Cooley S, He F, Bachanova V, Vercellotti GM, DeFor TE, Curtsinger JM, Robertson P, Grzywacz B, Conlon KC, Waldmann TA, McKenna DH, Blazar BR, Weisdorf DJ, Miller JS.

Blood Adv. 2019 Jul 9;3(13):1970-1980. doi: 10.1182/bloodadvances.2018028332.

3.

Cell therapies for trauma and critical care medicine: critical issues in translation for cellular and novel therapies in trauma and critical care.

Stroncek DF, Mathew AJ, McKenna DH.

Transfusion. 2019 Feb;59(S1):854-857. doi: 10.1111/trf.14832. No abstract available.

PMID:
30737821
4.

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.

Matthay MA, Calfee CS, Zhuo H, Thompson BT, Wilson JG, Levitt JE, Rogers AJ, Gotts JE, Wiener-Kronish JP, Bajwa EK, Donahoe MP, McVerry BJ, Ortiz LA, Exline M, Christman JW, Abbott J, Delucchi KL, Caballero L, McMillan M, McKenna DH, Liu KD.

Lancet Respir Med. 2019 Feb;7(2):154-162. doi: 10.1016/S2213-2600(18)30418-1. Epub 2018 Nov 16.

PMID:
30455077
5.

Current practices for viability testing of cryopreserved cord blood products: an international survey by the cellular therapy team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative.

Takanashi M, Selogie E, Reems JA, Stroncek D, Fontaine MJ, Girdlestone J, Garritsen HSP, Young P, McKenna DH, Szczepiorkowski ZM; Biomedical Excellence for Safer Transfusion (BEST) Collaborative.

Transfusion. 2018 Sep;58(9):2184-2191. doi: 10.1111/trf.14777.

PMID:
30204955
6.

Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution.

Williams SM, Sumstad D, Kadidlo D, Curtsinger J, Luo X, Miller JS, McKenna DH Jr.

Transfusion. 2018 Jun;58(6):1458-1467. doi: 10.1111/trf.14564. Epub 2018 Mar 12.

7.

Optimal Storage Conditions for Apheresis Research (OSCAR): a Biomedical Excellence for Safer Transfusion (BEST) Collaborative study.

Gniadek TJ, Garritsen HSP, Stroncek D, Szczepiorkowski ZM, McKenna DH; Biomedical Excellence for Safer Transfusion (BEST) Collaborative.

Transfusion. 2018 Feb;58(2):461-469. doi: 10.1111/trf.14429. Epub 2017 Dec 6.

PMID:
29210068
8.

Impact of starting material (fresh versus cryopreserved marrow) on mesenchymal stem cell culture.

Kaplan A, Sackett K, Sumstad D, Kadidlo D, McKenna DH.

Transfusion. 2017 Sep;57(9):2216-2219. doi: 10.1111/trf.14192. Epub 2017 Jun 26.

PMID:
28653392
9.

Clinical methods of cryopreservation for donor lymphocyte infusions vary in their ability to preserve functional T-cell subpopulations.

Worsham DN, Reems JA, Szczepiorkowski ZM, McKenna DH, Leemhuis T, Mathew AJ, Cancelas JA; Biomedical Excellence for Safer Transfusion (BEST) Collaborative Group.

Transfusion. 2017 Jun;57(6):1555-1565. doi: 10.1111/trf.14112. Epub 2017 Apr 28.

PMID:
28453219
10.

Manufacturing Differences Affect Human Bone Marrow Stromal Cell Characteristics and Function: Comparison of Production Methods and Products from Multiple Centers.

Liu S, de Castro LF, Jin P, Civini S, Ren J, Reems JA, Cancelas J, Nayak R, Shaw G, O'Brien T, McKenna DH, Armant M, Silberstein L, Gee AP, Hei DJ, Hematti P, Kuznetsov SA, Robey PG, Stroncek DF.

Sci Rep. 2017 Apr 27;7:46731. doi: 10.1038/srep46731.

11.

How do i participate in T-cell immunotherapy?

Suhoski Davis MM, McKenna DH, Norris PJ.

Transfusion. 2017 May;57(5):1115-1121. doi: 10.1111/trf.14098. Epub 2017 Apr 5. Review.

PMID:
28380265
12.

Impact of Delayed Infusion Time in Umbilical Cord Blood Transplantation.

Mitchell R, Wagner JE, Brunstein C, Cao Q, McKenna DH, Verneris MR.

Biol Blood Marrow Transplant. 2017 May;23(5):836-839. doi: 10.1016/j.bbmt.2017.02.010. Epub 2017 Feb 15.

13.

Improved Post-Thaw Function and Epigenetic Changes in Mesenchymal Stromal Cells Cryopreserved Using Multicomponent Osmolyte Solutions.

Pollock K, Samsonraj RM, Dudakovic A, Thaler R, Stumbras A, McKenna DH, Dosa PI, van Wijnen AJ, Hubel A.

Stem Cells Dev. 2017 Jun 1;26(11):828-842. doi: 10.1089/scd.2016.0347. Epub 2017 Mar 15.

14.

Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials.

McKenna DH Jr, Sumstad D, Kadidlo DM, Batdorf B, Lord CJ, Merkel SC, Koellner CM, Curtsinger JM, June CH, Riley JL, Levine BL, Miller JS, Brunstein CG, Wagner JE, Blazar BR, Hippen KL.

Cytotherapy. 2017 Feb;19(2):250-262. doi: 10.1016/j.jcyt.2016.10.011. Epub 2016 Nov 22.

15.

Combinations of Osmolytes, Including Monosaccharides, Disaccharides, and Sugar Alcohols Act in Concert During Cryopreservation to Improve Mesenchymal Stromal Cell Survival.

Pollock K, Yu G, Moller-Trane R, Koran M, Dosa PI, McKenna DH, Hubel A.

Tissue Eng Part C Methods. 2016 Nov;22(11):999-1008. Epub 2016 Oct 27.

16.

Impact of Graft-Recipient ABO Compatibility on Outcomes after Umbilical Cord Blood Transplant for Nonmalignant Disease.

Kudek MR, Shanley R, Zantek ND, McKenna DH, Smith AR, Miller WP.

Biol Blood Marrow Transplant. 2016 Nov;22(11):2019-2024. doi: 10.1016/j.bbmt.2016.07.019. Epub 2016 Aug 2.

17.

Algorithm-driven optimization of cryopreservation protocols for transfusion model cell types including Jurkat cells and mesenchymal stem cells.

Pollock K, Budenske JW, McKenna DH, Dosa PI, Hubel A.

J Tissue Eng Regen Med. 2017 Oct;11(10):2806-2815. doi: 10.1002/term.2175. Epub 2016 May 27.

18.

Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect.

Brunstein CG, Miller JS, McKenna DH, Hippen KL, DeFor TE, Sumstad D, Curtsinger J, Verneris MR, MacMillan ML, Levine BL, Riley JL, June CH, Le C, Weisdorf DJ, McGlave PB, Blazar BR, Wagner JE.

Blood. 2016 Feb 25;127(8):1044-51. doi: 10.1182/blood-2015-06-653667. Epub 2015 Nov 12.

19.

Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs.

Phinney DG, Di Giuseppe M, Njah J, Sala E, Shiva S, St Croix CM, Stolz DB, Watkins SC, Di YP, Leikauf GD, Kolls J, Riches DW, Deiuliis G, Kaminski N, Boregowda SV, McKenna DH, Ortiz LA.

Nat Commun. 2015 Oct 7;6:8472. doi: 10.1038/ncomms9472.

20.

Systemic Administration of Human Bone Marrow-Derived Mesenchymal Stromal Cell Extracellular Vesicles Ameliorates Aspergillus Hyphal Extract-Induced Allergic Airway Inflammation in Immunocompetent Mice.

Cruz FF, Borg ZD, Goodwin M, Sokocevic D, Wagner DE, Coffey A, Antunes M, Robinson KL, Mitsialis SA, Kourembanas S, Thane K, Hoffman AM, McKenna DH, Rocco PR, Weiss DJ.

Stem Cells Transl Med. 2015 Nov;4(11):1302-16. doi: 10.5966/sctm.2014-0280. Epub 2015 Sep 16.

21.

Freshly thawed and continuously cultured human bone marrow-derived mesenchymal stromal cells comparably ameliorate allergic airways inflammation in immunocompetent mice.

Cruz FF, Borg ZD, Goodwin M, Sokocevic D, Wagner D, McKenna DH, Rocco PR, Weiss DJ.

Stem Cells Transl Med. 2015 Jun;4(6):615-24. doi: 10.5966/sctm.2014-0268. Epub 2015 Apr 29.

22.

Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome.

Liu KD, Wilson JG, Zhuo H, Caballero L, McMillan ML, Fang X, Cosgrove K, Calfee CS, Lee JW, Kangelaris KN, Gotts JE, Rogers AJ, Levitt JE, Wiener-Kronish JP, Delucchi KL, Leavitt AD, McKenna DH, Thompson BT, Matthay MA.

Ann Intensive Care. 2014 Jul 3;4:22. doi: 10.1186/s13613-014-0022-z. eCollection 2014.

23.

Postthaw characterization of umbilical cord blood: markers of storage lesion.

Hubel A, Spindler R, Curtsinger JM, Lindgren B, Wiederoder S, McKenna DH.

Transfusion. 2015 May;55(5):1033-9. doi: 10.1111/trf.12971. Epub 2014 Dec 19.

24.

Clinical mesenchymal stromal cell products undergo functional changes in response to freezing.

Pollock K, Sumstad D, Kadidlo D, McKenna DH, Hubel A.

Cytotherapy. 2015 Jan;17(1):38-45. doi: 10.1016/j.jcyt.2014.06.008. Epub 2014 Oct 24.

25.

A reproducible immunopotency assay to measure mesenchymal stromal cell-mediated T-cell suppression.

Bloom DD, Centanni JM, Bhatia N, Emler CA, Drier D, Leverson GE, McKenna DH Jr, Gee AP, Lindblad R, Hei DJ, Hematti P.

Cytotherapy. 2015 Feb;17(2):140-51. doi: 10.1016/j.jcyt.2014.10.002. Epub 2014 Nov 21.

26.

Cell therapy product administration and safety: data capture and analysis from the Production Assistance for Cellular Therapies (PACT) program.

Lindblad RW, Ibenana L, Wagner JE, McKenna DH Jr, Hei DJ, Hematti P, Couture LA, Silberstein LE, Armant M, Rooney CM, Gee AP, Welniak LA, Heath Mondoro T, Wood DA, Styers D.

Transfusion. 2015 Mar;55(3):674-9. doi: 10.1111/trf.12881. Epub 2014 Oct 14. Review. No abstract available.

27.

Impact of long-term cryopreservation on single umbilical cord blood transplantation outcomes.

Mitchell R, Wagner JE, Brunstein CG, Cao Q, McKenna DH, Lund TC, Verneris MR.

Biol Blood Marrow Transplant. 2015 Jan;21(1):50-4. doi: 10.1016/j.bbmt.2014.09.002. Epub 2014 Sep 28.

28.

Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia.

Asmussen S, Ito H, Traber DL, Lee JW, Cox RA, Hawkins HK, McAuley DF, McKenna DH, Traber LD, Zhuo H, Wilson J, Herndon DN, Prough DS, Liu KD, Matthay MA, Enkhbaatar P.

Thorax. 2014 Sep;69(9):819-25. doi: 10.1136/thoraxjnl-2013-204980. Epub 2014 Jun 2.

29.

Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response.

Olin MR, Low W, McKenna DH, Haines SJ, Dahlheimer T, Nascene D, Gustafson MP, Dietz AB, Clark HB, Chen W, Blazar B, Ohlfest JR, Moertel C.

J Immunother Cancer. 2014 Feb 18;2:4. doi: 10.1186/2051-1426-2-4. eCollection 2014.

30.

Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.

Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lewis D, Hippen K, McGlave P, Weisdorf DJ, Blazar BR, Miller JS.

Blood. 2014 Jun 19;123(25):3855-63. doi: 10.1182/blood-2013-10-532531. Epub 2014 Apr 9.

31.

An update from the United States National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) program: a decade of cell therapy.

Wood D, Wesselschmidt R, Hematti P, Gee AP, Rooney C, Silberstein L, Armant M, Couture L, Wagner JE, McKenna DH Jr, Hei D, Mondoro TH, Welniak L, Lindblad R.

Clin Transl Sci. 2014 Apr;7(2):93-9. doi: 10.1111/cts.12148. Epub 2014 Mar 21. No abstract available.

32.

Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation.

McAuley DF, Curley GF, Hamid UI, Laffey JG, Abbott J, McKenna DH, Fang X, Matthay MA, Lee JW.

Am J Physiol Lung Cell Mol Physiol. 2014 May 1;306(9):L809-15. doi: 10.1152/ajplung.00358.2013. Epub 2014 Feb 14.

33.

Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.

Kharbanda S, Smith AR, Hutchinson SK, McKenna DH, Ball JB, Lamb LS Jr, Agarwal R, Weinberg KI, Wagner JE Jr.

Biol Blood Marrow Transplant. 2014 Apr;20(4):581-6. doi: 10.1016/j.bbmt.2013.12.564. Epub 2013 Dec 24.

34.

Complement fragment 3a priming of umbilical cord blood progenitors: safety profile.

Brunstein CG, McKenna DH, DeFor TE, Sumstad D, Paul P, Weisdorf DJ, Ratajczak M, Laughlin MJ, Wagner JE.

Biol Blood Marrow Transplant. 2013 Oct;19(10):1474-9. doi: 10.1016/j.bbmt.2013.07.016. Epub 2013 Jul 25.

35.

Adoptive transfer of umbilical cord blood-derived regulatory T cells and early viral reactivation.

Brunstein CG, Blazar BR, Miller JS, Cao Q, Hippen KL, McKenna DH, Curtsinger J, McGlave PB, Wagner JE.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1271-3. doi: 10.1016/j.bbmt.2013.06.004. Epub 2013 Jun 25. No abstract available.

36.

Cell therapy for lung diseases. Report from an NIH-NHLBI workshop, November 13-14, 2012.

Matthay MA, Anversa P, Bhattacharya J, Burnett BK, Chapman HA, Hare JM, Hei DJ, Hoffman AM, Kourembanas S, McKenna DH, Ortiz LA, Ott HC, Tente W, Thébaud B, Trapnell BC, Weiss DJ, Yuan JX, Blaisdell CJ.

Am J Respir Crit Care Med. 2013 Aug 1;188(3):370-5. doi: 10.1164/rccm.201303-0522WS. Review.

37.

Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria.

Lee JW, Krasnodembskaya A, McKenna DH, Song Y, Abbott J, Matthay MA.

Am J Respir Crit Care Med. 2013 Apr 1;187(7):751-60. doi: 10.1164/rccm.201206-0990OC.

38.

Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions.

Klingemann H, Grodman C, Cutler E, Duque M, Kadidlo D, Klein AK, Sprague KA, Miller KB, Comenzo RL, Kewalramani T, Yu N, Van Etten RA, McKenna DH.

Transfusion. 2013 Feb;53(2):412-8; quiz 411. doi: 10.1111/j.1537-2995.2012.03764.x. Epub 2012 Jun 28.

39.

Natural killer cells: a review of manufacturing and clinical utility.

Koepsell SA, Miller JS, McKenna DH Jr.

Transfusion. 2013 Feb;53(2):404-10. doi: 10.1111/j.1537-2995.2012.03724.x. Epub 2012 Jun 7. Review. No abstract available.

PMID:
22670662
40.

Clinical production and therapeutic applications of alloreactive natural killer cells.

McKenna DH, Kadidlo DM, Cooley S, Miller JS.

Methods Mol Biol. 2012;882:491-507. doi: 10.1007/978-1-61779-842-9_28.

PMID:
22665252
41.

Successful "in-flight" activation of natural killer cells during long-distance shipping.

Koepsell SA, Kadidlo DM, Fautsch S, McCullough J, Klingemann H, Wagner JE, Miller JS, McKenna DH Jr.

Transfusion. 2013 Feb;53(2):398-403. doi: 10.1111/j.1537-2995.2012.03695.x. Epub 2012 May 11.

42.

Factors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiovascular Cell Therapy Research Network (CCTRN) study.

Richman S, Gee AP, McKenna DH, Traverse JH, Henry TD, Fisk D, Pepine CJ, Bloom J, Willerson JT, Prater K, Zhao D, Koç JR, Anwaruddin S, Taylor DA, Cogle CR, Moyé LA, Simari RD, Skarlatos SI.

Transfusion. 2012 Oct;52(10):2225-33. doi: 10.1111/j.1537-2995.2011.03543.x. Epub 2012 Feb 10.

43.

Factors predicting single-unit predominance after double umbilical cord blood transplantation.

Ramirez P, Wagner JE, DeFor TE, Blazar BR, Verneris MR, Miller JS, McKenna DH, Weisdorf DJ, McGlave PB, Brunstein CG.

Bone Marrow Transplant. 2012 Jun;47(6):799-803. doi: 10.1038/bmt.2011.184. Epub 2011 Sep 26.

44.

Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity.

Hippen KL, Merkel SC, Schirm DK, Sieben CM, Sumstad D, Kadidlo DM, McKenna DH, Bromberg JS, Levine BL, Riley JL, June CH, Scheinberg P, Douek DC, Miller JS, Wagner JE, Blazar BR.

Sci Transl Med. 2011 May 18;3(83):83ra41. doi: 10.1126/scitranslmed.3001809.

45.

Interlaboratory assessment of a novel colony-forming unit assay: a multicenter study by the cellular team of Biomedical Excellence for Safer Transfusion (BEST) collaborative.

Nawrot M, McKenna DH, Sumstad D, McMannis JD, Szczepiorkowski ZM, Belfield H, Grassman E, Temples T, Nielsen D, Yuan N, Wognum B, Reems JA.

Transfusion. 2011 Sep;51(9):2001-5. doi: 10.1111/j.1537-2995.2011.03153.x. Epub 2011 May 13.

PMID:
21569039
46.

Gene expression changes with differentiation of cord blood stem cells to respiratory epithelial cells: a preliminary observation.

Berger MJ, Minnerath SR, Adams SD, Tigges BM, Sprague SL, McKenna DH Jr.

Stem Cell Res Ther. 2011 Apr 13;2(2):19. doi: 10.1186/scrt60.

47.

Umbilical cord blood: current status and future directions.

McKenna DH, Brunstein CG.

Vox Sang. 2011 Jan;100(1):150-62. doi: 10.1111/j.1423-0410.2010.01409.x. Review.

PMID:
21175665
48.

Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.

Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, Defor T, Levine BL, June CH, Rubinstein P, McGlave PB, Blazar BR, Wagner JE.

Blood. 2011 Jan 20;117(3):1061-70. doi: 10.1182/blood-2010-07-293795. Epub 2010 Oct 15.

49.

Therapeutic potential of mesenchymal stem cells for severe acute lung injury.

Matthay MA, Thompson BT, Read EJ, McKenna DH Jr, Liu KD, Calfee CS, Lee JW.

Chest. 2010 Oct;138(4):965-72. doi: 10.1378/chest.10-0518. Review.

50.

LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.

Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Simpson LM, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Baraniuk S, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyè LA, Simari RD; Cardiovascular Cell Therapy Research Network.

Tex Heart Inst J. 2010;37(4):412-20.

Supplemental Content

Loading ...
Support Center